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Background. B-type natriuretic peptide (BNP) levels are re-
liably elevated in patients with congestive heart failure (CHF)
and therefore helpful in its diagnosis. However, kidney disease
results in elevated BNP levels independently of CHF. Accord-
ingly, the impact of kidney disease on the benefit of BNP testing
needs to be scrutinized.
Methods. This study evaluated patients with and without kid-
ney disease [glomerular filtration rate (GFR) less than 60 mL/
min/1.73m2) presenting with acute dyspnea. A total of 452 con-
secutive patients (240 with kidney disease and 212 without kid-
ney disease) were randomly assigned to a diagnostic strategy
with (BNP group) or without (control group) the use of BNP
levels provided by a rapid bedside assay.
Results. Patients with kidney disease were older, more often
had CHF as the cause of acute dyspnea, and more often died
in-hospital or within 30 days as compared to patients without
kidney disease. In patients without kidney disease, BNP testing
significantly reduced median time to discharge (from 9.5 days to
2.5 days) (P = 0.003) and total cost of treatment (from $7184 to
$4151) (P = 0.004). In contrast, in patients with kidney disease,
time to discharge and total cost of treatment were similar in
both groups.
Conclusion. When applying BNP cut-off values without ad-
justment for the presence of kidney disease, the use of BNP
levels does significantly improve the management of patients
without kidney disease, but not of those with kidney disease.
Acute dyspnea is among the most common symptoms
in patients with kidney disease [1–5]. Unfortunately, the
rapid and accurate identification of the underlying causes
remains a clinical challenge. Congestive heart failure
(CHF) is a very important cause. The interaction between
cardiac and kidney disease has attained increasing recog-
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nition [1, 2]. Kidney disease has been shown to be the
most consistent independent predictor of adverse out-
come in patients with acute myocardial infarction, stable
coronary artery disease, hypertension, and CHF [3–10].
CHF is the common terminal disease state of cardiac dis-
orders. Accordingly, the prevalence of kidney disease in
the CHF population is high.
CHF is the most frequent cause of hospitalization in
patients older than 65 years of age and these hospital-
izations contribute significantly to the enormous cost of
the disease. It is estimated that in the United States in
2001, more than $24 billion was spent as direct cost for
the care of patients with heart failure [11–14]. Therefore,
cost-effective diagnosis and management is of paramount
importance. However, the symptoms and signs of heart
failure are neither sensitive nor specific, and considerably
overlap with those of pulmonary disease [13–16]. Mis-
diagnosis of CHF causes morbidity, and increases time
to discharge and treatment cost, because treatments for
CHF may be hazardous to patients with other conditions
such as chronic obstructive pulmonary disease (COPD),
and vice versa [17, 18].
B-type natriuretic peptide (BNP) is a 32 amino acid
polypeptide that is reliably elevated in the setting of CHF
and recent studies suggest that it may therefore be very
helpful in its diagnosis [15, 16, 19]. BNP is secreted from
the cardiac ventricles in response to ventricular volume
expansion and pressure overload [20]. The physiologic ef-
fects of this peptide include decreased peripheral vascular
resistance and increased natriuresis. The kidney seems to
play an important role in the clearance of BNP [20]. This
interference mandates to scrutinize, whether the promis-
ing results obtained for BNP testing for acute dyspnea
in unselected patients with predominantly normal renal
function [15, 16, 19, 21] can be extrapolated to patients
with kidney disease.
This study sought to evaluate whether a BNP-guided
diagnostic strategy, applying identical cut-off values ir-
respective of the presence or absence of kidney dis-
ease, would improve the evaluation and management of
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patients with and without mild to moderate kidney dis-
ease presenting with acute dyspnea to the emergency
department.
METHODS
Setting and study population
This study specifically evaluated the outcome of pa-
tients with and without mild to moderate kidney disease
in the BNP for Acute Shortness of Breath Evaluation
(BASEL) study [21]. At the time the BASEL study pro-
tocol was devised no data were available regarding the
accuracy of BNP testing in patients with severe kidney
disease. Accordingly, patients with a baseline serum cre-
atinine above 250 lmol/L were excluded. The BASEL
study was a prospective, randomized, single-blind study
conducted in the emergency department of the University
Hospital in Basel, Switzerland, from May 2001 to April
2002. The study was carried out according to the princi-
ples of the Declaration of Helsinki and approved by our
local ethical committee. Written informed consent was
obtained from all participating patients.
To be eligible for the study, a patient had to present
with shortness of breath as the primary complaint and
no obvious traumatic cause of dyspnea. Patients in car-
diogenic shock were excluded. A total of 452 consecutive
patients were enrolled in the BASEL study and randomly
assigned according to a computer-generated randomiza-
tion scheme 1:1 without stratification to receive a diag-
nostic strategy with (N = 225, including 113 patients with
kidney disease, BNP group) or without (N = 227, includ-
ing 127 patients with kidney disease, control group) the
use of BNP levels provided by a rapid bedside assay.
Kidney disease and glomerular filtration rate (GFR)
As suggested by the National Kidney Foundation Kid-
ney Disease Outcomes Quality Initiative, kidney dis-
ease was prospectively defined and considered present
if the calculated GFR was less than 60 mL/min/1.73m2
at presentation [22]. We calculated GFR with the use
of the abbreviated Modification of Diet in Renal Dis-
ease Study equation [23, 24]: GFR (in mL/min/1.73m2
of body-surface-area) = 186 × (serum creatinine in
mg/dL)−1.154 × (age in years)−0.203 × 0.742 in female sub-
jects × 1.210 in black subjects.
This equation is based on data from Levey et al [24]
on 1628 subjects with 558 in the validation set. A ve-
nous blood specimen for serum creatinine was drawn on
presentation. All samples were analyzed in a central lab-
oratory with the use of an enzymatic kit (CREA Plus)
(Boehringer Mannheim Systems, Mannheim, Germany).
Routine clinical assessment
All patients underwent an initial clinical assessment
that included clinical history, physical examination, elec-
trocardiogram (ECG), pulse oximetry, blood tests, in-
cluding arterial blood gas analysis (when indicated), and
chest x-ray. Echocardiography and pulmonary function
tests were strongly recommended in the emergency de-
partment on an outpatient basis or in the hospital if the
patient was admitted.
Measurement and interpretation of BNP levels
During initial evaluation, at the time of venipuncture
for routine blood tests, a venous specimen of blood (5 mL)
was collected into tubes containing potassium ethylene-
diaminetetraacetic acid (EDTA). In a 15-minute period,
BNP was measured by using a rapid fluorescence im-
munoassay (Biosite Diagnostics, La Jolla, CA, USA).
Precision, analytic sensitivity, and stability characteris-
tics of the system have been previously described [25]. In
brief, the coefficient of variation for intra-assay precision
has been reported to be 9.5%, 12.0%, and 13.9%, and the
coefficient of variation for interassay precision is known
to be 10.0%, 12.4%, and 14.8% for BNP levels of 28.8,
584.0, and 1180.0 pg/mL, respectively [25]. The analytic
sensitivity was <5.0 pg/mL, with a measurable range of 0
to 1300 pg/mL.
In the BNP-guided group, diagnostic and therapeutic
decisions were not based on BNP levels only, but the in-
formation provided by the BNP level was integrated with
the clinical impression as previously described [26]. In
brief, we used two BNP cut-off levels (100 and 500 pg/mL)
to separate CHF from other causes of dyspnea. In patients
with a BNP level below 100 pg/mL, CHF was considered
unlikely and alternative causes of dyspnea had to be pur-
sued. In patients with a BNP level above 500 pg/mL, CHF
was considered likely and rapid therapy with diuretics,
nitroglycerin, angiotensin-converting enzyme (ACE) in-
hibitors, and morphine was recommended. For patients
with BNP levels between 100 and 500 pg/mL, the proto-
col recommended clinical judgment and possible further
diagnostic testing. Importantly, these cut-off values were
applied regardless of the presence or absence of kidney
disease. Patients in the control group were evaluated and
managed according to the most recent clinical practice
guidelines [13, 14].
End points
Time to discharge and cost of treatment were defined
as the primary end points of this study. Time to discharge
was defined as the time interval from presentation to the
emergency department to discharge. Patients who died in
hospital were excluded from the calculation of this end
point. As cost-charge ratios have not been defined for the
majority of services and departments at our institution,
hospital charges were collected as the most appropriate
estimate for true costs [27–28]. To avoid imbalance due
to varying hospital contracts with different insurances or
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different insurance classes, charges were standardized to
the actual rates for patients with general insurance living
in Basel. For the measurement of BNP, the current re-
imbursement in Switzerland ($47) was used. Secondary
end points included in hospital mortality, 30-day mor-
tality, and 30-day readmission rate. All end points were
assessed by physicians not involved in patient care and
blinded to the assigned group using all medical records
pertaining to the patient.
Statistical analysis
The statistical analyses were performed using the
SPSS/PC, version 11.0 (SPSS Inc., Chicago, IL, USA)
software package. A statistical significance level of 0.05
was used. All data were analyzed on an intention-to-treat
basis. Comparisons were made using the t test, Mann-
Whitney U test, Fisher exact test and chi-square test as
appropriate. All hypothesis testing was two-tailed. These
analyses concentrating on patients with kidney disease
were pre-specified in the BASEL study protocol.
RESULTS
A total of 240 consecutive patients with kidney dis-
ease (mean GFR 42 mL/min/1.73m2) were enrolled in
this trial. These patients differed significantly from the
patients enrolled without kidney disease (Table 1). Pa-
tients with kidney disease were older, more often women,
and their history more often included coronary artery
disease, hypertension, diabetes, and stroke or peripheral
vascular disease, but less often included COPD. Among
symptoms, paroxysmal nocturnal dyspnea, weight gain,
and nocturia were more common, whereas coughing
and expectoration were less common. Among signs, ele-
vated jugular venous pressure, rales, and lower-extremity
edema were more common. Accordingly, CHF was the
final discharge diagnosis twice as often in patients with
kidney disease as compared to patients without kidney
disease. Obstructive pulmonary disease, anxiety disorder,
and other disorders less often were the cause of the acute
dyspnea. Patients with kidney disease had significantly
higher rates of hospital admission, as well as in-hospital
and 30-day mortality.
Among patients with kidney disease, the baseline char-
acteristics were well matched between the study groups.
The mean age was 76 years. Comorbidities were extensive
and included coronary artery disease and hypertension,
each in more than 60% of patients, pulmonary disease in
nearly half, and diabetes in one forth of patients. Short-
ness of breath was present at rest in 30% and at level
ground in 58% of patients. Coughing (45%), chest pain
(35%), nocturia (40%), and expectoration (30%) were
the most common accompanying symptoms. On physi-
cal examination, tachypnea, rales, and lower-extremity
edema were present in approximately 50% of patients.
CHF, exacerbated obstructive pulmonary disease, and
pneumonia (in 65%, 10%, and 12% of patients, respec-
tively) were the most common discharge diagnoses over-
all with similar distributions in both groups. BNP levels
stratified for the final discharge diagnosis in the BNP
group are presented in Table 2.
As shown in Table 3, a nonsignificant reduction in the
time interval to initiation of the appropriate therapy ac-
cording to the final discharge diagnosis was seen in the
BNP group. The use of BNP levels did only slightly reduce
the need for hospital admission (88% versus 94%) (P =
0.10) or intensive care (18% versus 26%) (P = 0.12). Me-
dian time to discharge was 11.0 days in the BNP group as
compared with 13.0 days in the control group (P = 0.29)
Fig. 1). Total cost of treatment was $6658 (95% CI 5501
to 7815) in the BNP group as compared with $7328 (95%
CI 6146 to 8510) (P = 0.43) in the control group (Fig. 2).
In contrast to these results, BNP testing did have a ma-
jor impact on the management of patients without kid-
ney disease: Median time to discharge was significantly
reduced from 9.5 days (interquartile range, 1.0 to 18.0)
in the control group to 2.5 days (interquartile range, 0.25
to 11.0) in the BNP group (P = 0.003). In addition, total
cost of treatment was reduced from $7184 (95% CI 5570
to 8797) in the control group to $4151 (95% CI 2809 to
5492) (P = 0.004) in the BNP group.
DISCUSSION
Among patients presenting with acute dyspnea, pa-
tients with kidney disease differed significantly from
those without. Most important, patients with kidney dis-
ease were older, more often suffered from CHF, and more
often died in hospital and within 30 days. In patients with
kidney disease, the use of BNP levels did not significantly
improve patient outcome. There was a trend toward a
reduced need for hospital admission and intensive care,
as well as reduced time to discharge. However, none of
these differences were statistically significant. This find-
ing is in contrast to the considerable improvement seen
in patients without kidney disease and unselected patient
cohorts with predominately normal kidney function [7–9,
16–18, 21]. Therefore, kidney disease seems to interfere
with and limit the usefulness of BNP levels in the diagno-
sis of CHF, if cut-off values without adjustment for kidney
function are applied.
Our study is complementary to the Breathing Not
Properly Multinational Study [29] and our findings ex-
tend the conclusions drawn from that observational study
in which BNP levels were validated against a retro-
spectively adjudicated diagnosis of CHF by independent
cardiologists. Both studies indicated that higher cut-off
values should be applied in patients with kidney dis-
ease. The mean BNP level in patients with a non-cardiac
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Table 1. Baseline characteristics, final discharge diagnosis, and outcomes in patients with and without kidney disease
Kidney disease No kidney disease
All BNP Control All BNP Control
(N = 240) (N = 113) (N = 127) (N = 212) (N = 112) (N = 100) P value
Age years 76 ± 12 76 ± 12 75 ± 11 65 ± 17 65 ± 17 65 ± 17 <0.001
Gender 0.012
Male 126 (52) 58 (51) 68 (54) 136 (64) 74 (66) 62 (62)
Female 114 (48) 55 (49) 59 (46) 76 (36) 38 (34) 38 (38)
History
Coronary artery disease 148 (62) 69 (61) 79 (62) 77 (36) 44 (39) 33 (33) <0.001
Arterial hypertension 148 (62) 67 (59) 81 (64) 89 (42) 46 (41) 43 (43) <0.001
Diabetes mellitus 68 (28) 30 (27) 38 (30) 35 (17) 17 (15) 18 (18) 0.003
COPD 61 (25) 33 (29) 28 (22) 79 (37) 42 (38) 37 (37) 0.007
Pulmonary embolism 16 (7) 10 (9) 6 (5) 15 (7) 8 (7) 7 (7) 0.864
Any pulmonary disease 110 (46) 56 (50) 54 (43) 116 (55) 63 (56) 53 (53) 0.059
Depressive disorder 19 (8) 6 (5) 13 (10) 17 (8) 9 (8) 8 (8) 0.968
Strokea 68 (28) 29 (26) 39 (31) 21 (10) 11 (10) 10 (10) <0.001
Deep vein thrombosis 24 (10) 12 (11) 12 (9) 17 (8) 7 (6) 10 (10) 0.464
Symptoms
Shortness of breath 0.138
Slight hill 26 (11) 16 (14) 10 (8) 39 (18) 16 (14) 23 (23)
Level ground 140 (58) 59 (52) 81 (64) 117 (55) 66 (59) 51 (51)
At rest 72 (30) 38 (34) 34 (27) 54 (26) 28 (25) 26 (26)
PND 108 (45) 45 (40) 63 (50) 58 (27) 34 (30) 24 (24) <0.001
Nocturia 96 (40) 41 (36) 55 (43) 40 (19) 19 (17) 21 (21) <0.001
Chest pain 84 (35) 44 (39) 40 (31) 70 (33) 32 (29) 38 (38) 0.657
Coughing 107 (45) 44 (39) 63 (50) 117 (55) 57 (51) 60 (60) 0.024
Expectoration 72 (30) 31 (27) 41 (32) 87 (41) 41 (37) 46 (46) 0.014
Fever 57 (24) 30 (27) 27 (21) 52 (25) 29 (26) 23 (23) 0.847
Vital status
Systolic blood pressure mm Hg 144 ± 31 142 ± 33 146 ± 30 146 ± 25 149 ± 25 143 ± 25 0.512
Diastolic blood pressure mm Hg 84 ± 20 82 ± 18 85 ± 21 88 ± 17 88 ± 16 87 ± 18 0.029
Heart rate per minute 96 ± 26 95 ± 25 98 ± 27 99 ± 23 97 ± 21 102 ± 25 0.230
Temperature ◦C 37.3 ± 1.0 37.4 ± 1.0 37.3 ± 1.0 37.4 ± 0.9 37.3 ± 1.0 37.5 ± 0.9 0.487
Signs
Tachypnea >20 per minute 121 (50) 60 (53) 61 (48) 89 (42) 46 (41) 43 (43) 0.073
Elevated JVP 49 (20) 23 (20) 26 (20) 15 (7) 9 (8) 6 (6) <0.001
Hepatojugular reflux 36 (15) 18 (16) 18 (14) 13 (6) 7 (6) 6 (6) 0.002
Rales 139 (58) 69 (61) 70 (55) 68 (32) 34 (30) 34 (34) <0.001
Wheezing 45 (19) 23 (20) 22 (17) 55 (26) 32 (29) 23 (23) 0.066
Hyper-resonant percussion 17 (7) 9 (8) 8 (6) 22 (10) 13 (12) 9 (9) 0.213
Dullness 28 (12) 14 (12) 14 (11) 18 (9) 6 (5) 12 (12) 0.265
Lower-extremity edema 100 (42) 46 (41) 54 (43) 56 (26) 27 (24) 29 (29) 0.001
Laboratory
GFR mL/min/1.73m2 42 ± 12 42 ± 12 42 ± 12 90 ± 31 89 ± 26 91 ± 36 <0.001
Serum albumin g/L 33 ± 6 33 ± 6 33 ± 5 34 ± 5 35 ± 5 34 ± 5 0.003
Hemoglobin g/dL 12.8 ± 2.3 12.8 ± 2.2 12.7 ± 2.4 14.3 ± 2.8 14.3 ± 2.0 14.4 ± 3.6 <0.001
Medications
ACE inhibitorsa 117 (49) 57 (50) 60 (47) 60 (28) 34 (30) 26 (26) <0.001
Diuretics 151 (63) 76 (67) 75 (59) 70 (33) 42 (38) 28 (28) <0.001
Final discharge diagnosis
Congestive heart failure 157 (65) 69 (61) 88 (69) 60 (28) 32 (29) 28 (28) <0.001
Obstructive pulmonary disease 24 (10) 14 (12) 10 (8) 52 (25) 37 (33) 15 (15) <0.001
Pulmonary embolism 14 (6) 7 (6) 7 (6) 7 (3) 3 (3) 4 (4) 0.202
Pneumonia 28 (12) 17 (15) 11 (9) 34 (16) 15 (13) 19 (19) 0.178
Anxiety disorder 1 (0.4) 0 1 (0.8) 15 (7) 7 (6) 8 (8) <0.001
Other diseaseb 20 (8) 8 (7) 12 (9) 39 (18) 18 (16) 21 (21) 0.002
Unknown cause 10 (4) 4 (4) 6 (5) 10 (5) 4 (4) 6 (6) 0.776
Abbreviations are: BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; JVP, jugular venous pressure; PND, paroxysmal nocturnal
dyspnea. Stroke, stroke or peripheral vascular disease; ACE, angiotensin-converting enzyme.
Data are presented as mean ± SD, median (interquartile range), or number of patients (%). P values are given for the comparison of patients with versus without
kidney disease. There were no statistically significant differences in the baseline characteristics between the control group and the BNP group.
aAngiotensin-converting-enzyme (ACE) inhibitor or angiotensin-receptor blocker.
bIncluding interstitial lung disease, pleural effusion, sepsis, and anemia.
cause of dyspnea and an estimated GFR of less than
60 mL/min/1.73m2 of body surface area was nearly
300 pg/mL in this study. This is three times the cut-off
value used for the exclusion of CHF. Accordingly, only
very few patients with kidney disease and non-cardiac
causes of acute dyspnea will present with BNP levels
below 100 pg/mL and can accordingly be diagnosed as
not having CHF. As the high negative predictive value
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Table 2. B-type natriuretic peptide levels (in pg/mL) stratified according to the final discharge diagnosis in the B-type natriuretic peptide group
Kidney disease No kidney disease
Mean ± SD Range Mean ± SD Range
Heart failure 906 ± 415 132–1300 550–421 14–1300
Obstructive pulmonary disease 178 ± 112 6–416 51 ± 56 0–225
Pulmonary embolism 242 ± 398 14–1130 111 ± 96 10–202
Pneumonia 553 ± 475 63–1300 288 ± 355 7–1300
Anxiety disorder None 47 ± 85 0–237
Other diseasea 315 ± 427 35–1300 133 ± 247 0–887
Unknown cause 511 ± 382 107–930 28 ± 20 7–55
aIncluding interstitial lung disease, pleural effusion, sepsis, and anemia.
Table 3. End points
Kidney disease (N = 240) No kidney disease (N = 212)
BNP group Control group BNP group Control group
(N= 113) (N = 127) P value (N= 112) (N= 100) P value
Time to treatment minutes 60 [0–149] 87 [20–196] 0.135 65 [15–156] 105 [19–221] 0.100
Time to discharge days 11.0 [4.0–19.0] 13.0 [8.0–19.0] 0.291 2.5 [0.25–11.0] 9.5 [1.0–18.0] 0.003
Hospital admission 99 (88) 119 (94) 0.103 70 (63) 74 (74) 0.073
Admission to intensive care 20 (18) 33 (26) 0.122 13 (12) 21 (21) 0.063
Cost of intensive care $ 979 (362–1597) 1269 (726–1811) 0.485 767 (1001–1433) 1830 (844–2817) 0.073
Total treatment cost $ 6658 (5501–7815) 7328 (6146–8510) 0.425 4151 (2809–5492) 7184 (5570–8797) 0.004
In hospital mortality 9 (8) 16 (13) 0.241 4 (4) 5 (5) 0.738
30-day mortality 15 (13) 20 (16) 0.588 7 (6) 8 (8) 0.620
30-day readmission rate 18 (16) 12 (9) 0.130 8 (7) 11 (11) 0.326
BNP is B-type natriuretic peptide. Data are presented as median [interquartile range], mean (95% CI), or number of patients (%).
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Fig. 1. Cumulative frequency distribution
curve displaying the time to discharge of pa-
tients with or without kidney disease in the
B-type natriuretic peptide (BNP) group ver-
sus the control group. BNP testing exclusively
reduced the time to discharge in patients with-
out kidney disease.
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Fig. 2. Total treatment cost in the control
group versus the B-type natriuretic peptide
(BNP) group in patients with and without kid-
ney disease. BNP testing exclusively reduced
total treatment cost in patients without kidney
disease. Boxes show means and I bars repre-
sent 95% confidence intervals.
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for CHF is widely seen as the most important feature of
BNP testing [15, 16, 19, 23], the failure to significantly
improve the management of patients with kidney disease
with the current federal Food and Drug Administration
(FDA)-approved cut-off value seems logical. Data from
the Breathing Not Properly Multinational Study [29] in-
dicate that approximately 225 pg/mL may be the best
cut-off point for patients with an estimated GFR of less
than 60 mL/min/1.73m2 of body surface area.
Another reason for a more limited impact of BNP test-
ing in patients with kidney disease may have been the low
incidence of noncardiac causes of acute dyspnea. CHF
was responsible for nearly two thirds of episodes, four
times the incidence of the second most common cause
(pneumonia). This CHF predominance in patients with
kidney disease and acute dyspnea was also noted the
Breathing Not Properly Multinational Study [29]. It ap-
pears as a particular strength of this study, that the study
population (mean age 76 years, extensive comorbidity)
was highly representative of the elderly patient popula-
tion with kidney disease in clinical practice [1, 2].
Several limitations apply to this study. First, the clini-
cal experience with BNP testing in patients with kidney
disease is limited. Our interpretation of BNP levels was
based on the data available when the study protocol was
devised. Further studies are necessary to find out whether
cut-off values corrected for age, gender, and GFR will
overcome the limitation of BNP testing in patients with
kidney disease [29, 30]. These trials are timely given the
significant morbidity and mortality in patients with kid-
ney disease and acute dyspnea. Second, randomization
was not stratified for kidney function. Therefore, it is reas-
suring to note that the baseline characteristics were well
matched between patients with kidney disease in both
groups. Third, it is important to note that an elevated
serum creatinine at baseline due to poor renal perfusion
or volume depletion may have biased the classification
by estimated GFR. Fourth, this analysis may have been
underpowered to detect a small but potentially clinically
meaningful benefit of BNP testing in patients with kid-
ney disease. Accordingly, larger studies should soon be
initiated.
CONCLUSION
When applying BNP cut-off values without adjustment
for the presence of kidney disease, the use of BNP levels
does significantly improve the management of patients
without kidney disease, but not of those with kidney
disease.
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